BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vuylsteke B, Reyniers T, De Baetselier I, Nöstlinger C, Crucitti T, Buyze J, Kenyon C, Wouters K, Laga M. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence. J Int AIDS Soc 2019;22:e25407. [PMID: 31663257 DOI: 10.1002/jia2.25407] [Cited by in Crossref: 31] [Cited by in F6Publishing: 47] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Mohareb AM, Larmarange J, Kim AY, Coffie PA, Kouamé MG, Boyd A, Freedberg KA, Hyle EP. Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. The Lancet HIV 2022;9:e585-94. [DOI: 10.1016/s2352-3018(22)00123-0] [Reference Citation Analysis]
2 Philpot SP, Murphy D, Chan C, Haire B, Fraser D, Grulich AE, Bavinton BR. Switching to Non-daily Pre-exposure Prophylaxis Among Gay and Bisexual Men in Australia: Implications for Improving Knowledge, Safety, and Uptake. Sex Res Social Policy 2022;:1-10. [PMID: 35730059 DOI: 10.1007/s13178-022-00736-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Traikiatphum J, Wongharn P, Moonwong J, Songtaweesin WN, Vitsupakorn S, Premgamone A, Kawichai S, Puthanakit T. Retention in event-driven PrEP among young Thai men who have sex with men at risk of HIV acquisition. Int J STD AIDS 2022;:9564624221106527. [PMID: 35653585 DOI: 10.1177/09564624221106527] [Reference Citation Analysis]
4 Molina J, Ghosn J, Assoumou L, Delaugerre C, Algarte-genin M, Pialoux G, Katlama C, Slama L, Liegeon G, Beniguel L, Ohayon M, Mouhim H, Goldwirt L, Spire B, Loze B, Surgers L, Pavie J, Lourenco J, Ben-mechlia M, Le Mestre S, Rojas-castro D, Costagliola D. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. The Lancet HIV 2022. [DOI: 10.1016/s2352-3018(22)00133-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Jongen VW, Zimmermann HML, Goedhart M, Bogaards JA, Davidovich U, Coyer L, de Vries HJC, Prins M, Hoornenborg E, Schim van der Loeff MF; Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative. Can we screen less frequently for STI among PrEP users? Assessing the effect of biannual STI screening on timing of diagnosis and transmission risk in the AMPrEP Study. Sex Transm Infect 2022:sextrans-2022-055439. [PMID: 35584898 DOI: 10.1136/sextrans-2022-055439] [Reference Citation Analysis]
6 Geretti AM, Mardh O, de Vries HJC, Winter A, McSorley J, Seguy N, Vuylsteke B, Gokengin D. Sexual transmission of infections across Europe: appraising the present, scoping the future. Sex Transm Infect 2022:sextrans-2022-055455. [PMID: 35537800 DOI: 10.1136/sextrans-2022-055455] [Reference Citation Analysis]
7 Eubanks A, Coulibaly B, Dembélé Keita B, Anoma C, Dah TTE, Mensah E, Maradan G, Bourrelly M, Mora M, Riegel L, Rojas Castro D, Yaya I, Spire B, Laurent C, Sagaon-Teyssier L; and the COHMSM-PrEP Study Group. Rate and Predictors of Ineffective HIV Protection in African Men Who Have Sex with Men Taking Pre-Exposure Prophylaxis. AIDS Behav 2022. [PMID: 35469111 DOI: 10.1007/s10461-022-03692-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhang J, Li C, Xu J, Hu Z, Rutstein SE, Tucker JD, Ong JJ, Jiang Y, Geng W, Wright ST, Cohen MS, Shang H, Tang W. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. The Lancet HIV 2022;9:e254-68. [DOI: 10.1016/s2352-3018(22)00030-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
9 Mizushima D, Takano M, Ando N, Uemura H, Yanagawa Y, Aoki T, Watanabe K, Ishizuka N, Oka S. A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo. Journal of Infection and Chemotherapy 2022. [DOI: 10.1016/j.jiac.2022.02.013] [Reference Citation Analysis]
10 Gillespie D, Couzens Z, de Bruin M, Hughes DA, Jones A, Ma R, Williams A, Wood F, Blee K, Bradshaw HS, Drayton R, Knapper C, Hood K. PrEP Use, Sexual Behaviour, and PrEP Adherence Among Men who have Sex with Men Living in Wales Prior to and During the COVID-19 Pandemic. AIDS Behav 2022. [PMID: 35182283 DOI: 10.1007/s10461-022-03618-4] [Reference Citation Analysis]
11 Saxton PJW, Azariah S, Cavadino A, Forster RF, Jenkins R, Werder SF, Southey K, Rich JG. Adherence, Sexual Behavior and Sexually Transmitted Infections in a New Zealand Prospective PrEP Cohort: 12 Months Follow-up and Ethnic Disparities. AIDS Behav 2022. [PMID: 35167038 DOI: 10.1007/s10461-022-03617-5] [Reference Citation Analysis]
12 Wang H, Wang Z, Huang X, Chen Y, Wang H, Cui S, Zhang J, Chu Z, Hu Q, Ding H, Qian H, Zou H, Tang W, Gao Y, Jin X, Liu Z, Zhang L, Zhao J, He X, Jiang Y, Geng W, Xu J, Shang H; China Real-World Oral Intake of PrEP (CROPrEP) Study Team. Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial. JAMA Netw Open 2022;5:e2148782. [PMID: 35171258 DOI: 10.1001/jamanetworkopen.2021.48782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 De Baetselier I, Vuylsteke B, Reyniers T, Smet H, Van den Bossche D, Kenyon C, Crucitti T. Worryingly high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium among men who have sex with men with recurrent sexually transmitted infections. Int J STD AIDS. [DOI: 10.1177/09564624211070704] [Reference Citation Analysis]
14 Laumen JGE, Van Dijck C, Abdellati S, De Baetselier I, Serrano G, Manoharan-Basil SS, Bottieau E, Martiny D, Kenyon C. Antimicrobial susceptibility of commensal Neisseria in a general population and men who have sex with men in Belgium. Sci Rep 2022;12:9. [PMID: 34997050 DOI: 10.1038/s41598-021-03995-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Kenyon C, Vanbaelen T, Van Dijck C. Recent insights suggest the need for the STI field to embrace a more eco-social conceptual framework: A viewpoint. Int J STD AIDS 2022;:9564624211064133. [PMID: 34982008 DOI: 10.1177/09564624211064133] [Reference Citation Analysis]
16 Apers L, Vanhamel J, Caluwaerts S, Platteau T, Kenyon C, Florence E. Impact of PrEP on a STI clinic in a Belgian context: a provider's perspective. Acta Clin Belg 2021;76:477-81. [PMID: 32468957 DOI: 10.1080/17843286.2020.1767995] [Reference Citation Analysis]
17 Van Dijck C, De Baetselier I, Cuylaerts V, Buyze J, Laumen J, Vuylsteke B, Kenyon C. Gonococcal bacterial load in PrEP users with Mycoplasma genitalium coinfection. Int J STD AIDS 2021;:9564624211048678. [PMID: 34727757 DOI: 10.1177/09564624211048678] [Reference Citation Analysis]
18 Newman DR, Matthias J, Rahman MM, Brantley A, Peterman TA. Repeat Syphilis Among HIV-Infected Men in Florida and Louisiana 2000-2018: Implications for Screening Recommendations. AIDS Patient Care STDS 2021;35:435-40. [PMID: 34739335 DOI: 10.1089/apc.2021.0081] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Hovaguimian F, Martin E, Reinacher M, Rasi M, Schmidt AJ, Bernasconi E, El Amari EB, Braun DL, Calmy A, Darling K, Christinet V, Depmeier C, Hauser C, Läuchli S, Notter J, Stoeckle M, Surial B, Vernazza P, Bruggmann P, Tarr P, Haerry D, Bize R, Low N, Lehner A, Böni J, Kouyos RD, Fehr JS, Hampel B. Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection. HIV Med 2021. [PMID: 34605153 DOI: 10.1111/hiv.13175] [Reference Citation Analysis]
20 Jin F, Amin J, Guy R, Vaccher S, Selvey C, Zablotska I, Holden J, Price K, Yeung B, Ogilvie E, Quichua GC, Clackett S, McNulty A, Smith D, Templeton DJ, Bavinton B, Grulich AE; Expanded PrEP Implementation in Communities New South Wales (EPIC-NSW) research group. Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia. AIDS 2021;35:1987-96. [PMID: 34101630 DOI: 10.1097/QAD.0000000000002970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 Kwan TH, Lui GCY, Lam TTN, Lee KCK, Wong NS, Chan DPC, Lee SS. Comparison between daily and on-demand PrEP (pre-exposure prophylaxis) regimen in covering condomless anal intercourse for men who have sex with men in Hong Kong: A randomized, controlled, open-label, crossover trial. J Int AIDS Soc 2021;24:e25795. [PMID: 34473402 DOI: 10.1002/jia2.25795] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Vuylsteke B, Reyniers T, Nöstlinger C, Smekens T, Kenyon C, Laga M. Can We Predict Incorrect PrEP Use in High HIV Risk Situations Among Men Who Have Sex With Men? An Analysis of Be-PrEP-ared, the Belgian PrEP Demonstration Study. J Acquir Immune Defic Syndr 2021;88:36-44. [PMID: 34081665 DOI: 10.1097/QAI.0000000000002741] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Jongen VW, Reyniers T, Ypma ZM, Schim van der Loeff MF, Davidovich U, Zimmermann HM, Coyer L, van den Elshout MA, de Vries HJ, Wouters K, Smekens T, Vuylsteke B, Prins M, Laga M, Hoornenborg E. Choosing event-driven and daily HIV pre-exposure prophylaxis - data from two European PrEP demonstration projects among men who have sex with men. J Int AIDS Soc 2021;24:e25768. [PMID: 34382345 DOI: 10.1002/jia2.25768] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
24 van Hoek AJ, Reitsema M, Xiridou M, van Sighem A, van Benthem B, Wallinga J, van Duijnhoven Y, van der Loeff MS, Prins M, Hoornenborg E; Amsterdam PrEP Project Team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative. Offering a choice of daily and event-driven preexposure prophylaxis for men who have sex with men in the Netherlands: a cost-effectiveness analysis. AIDS 2021;35:1677-82. [PMID: 34270490 DOI: 10.1097/QAD.0000000000002913] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Vanbaelen T, Van Dijck C, De Baetselier I, Florence E, Reyniers T, Vuylsteke B, Jacobs BK, Kenyon C. Screening for STIs is one of the main drivers of macrolide consumption in PrEP users. Int J STD AIDS 2021;:9564624211025940. [PMID: 34139924 DOI: 10.1177/09564624211025940] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
26 Meyers K, Wu Y, Shin KY, Hou J, Hu Q, Duan J, Li Y, He X. Salient Constructs for the Development of Shared Decision-Making Tools for HIV Pre-Exposure Prophylaxis Uptake and Regimen Choice: Behaviors, Behavioral Skills, and Beliefs. AIDS Patient Care STDS 2021;35:195-203. [PMID: 34037427 DOI: 10.1089/apc.2021.0066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kumar S, Haderxhanaj LT, Spicknall IH. Reviewing PrEP's Effect on STI Incidence Among Men Who Have sex with Men-Balancing Increased STI Screening and Potential Behavioral Sexual Risk Compensation. AIDS Behav 2021;25:1810-8. [PMID: 33242186 DOI: 10.1007/s10461-020-03110-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Laurent C, Dembélé Keita B, Yaya I, Le Guicher G, Sagaon-Teyssier L, Agboyibor MK, Coulibaly A, Traoré I, Malan JB, De Baetselier I, Eubanks A, Riegel L, Rojas Castro D, Fayé-Ketté H, Koné A, Diandé S, Dagnra CA, Serrano L, Diallo F, Mensah E, Dah TTE, Anoma C, Vuylsteke B, Spire B; CohMSM-PrEP Study Group. HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study. Lancet HIV 2021;8:e420-8. [PMID: 34048794 DOI: 10.1016/S2352-3018(21)00005-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
29 Wu HJ, Wen-Wei Ku S, Chang HH, Li CW, Ko NY, Strong C. Imperfect adherence in real life: a prevention-effective perspective on adherence to daily and event-driven HIV pre-exposure prophylaxis among men who have sex with men - a prospective cohort study in Taiwan. J Int AIDS Soc 2021;24:e25733. [PMID: 34018330 DOI: 10.1002/jia2.25733] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
30 Reyniers T, Zimmermann HML, Davidovich U, Vuylsteke B, Laga M, Hoornenborg E, Prins M, De Vries HJC, Nöstlinger C. The social meanings of PrEP use - A mixed-method study of PrEP use disclosure in Antwerp and Amsterdam. Sociol Health Illn 2021;43:1311-27. [PMID: 33997998 DOI: 10.1111/1467-9566.13283] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Jongen VW, Hoornenborg E, van den Elshout MA, Boyd A, Zimmermann HM, Coyer L, Davidovich U, Anderson PL, de Vries HJ, Prins M, Schim van der Loeff MF; Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP. J Int AIDS Soc 2021;24:e25708. [PMID: 33973373 DOI: 10.1002/jia2.25708] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
32 Hojilla JC, Marcus JL, Silverberg MJ, Hare CB, Herbers R, Hurley L, Satre DD, Volk JE. Early Adopters of Event-driven Human Immunodeficiency Virus Pre-exposure Prophylaxis in a Large Healthcare System in San Francisco. Clin Infect Dis 2020;71:2710-2. [PMID: 32494806 DOI: 10.1093/cid/ciaa474] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
33 de Block T, Laumen JGE, Van Dijck C, Abdellati S, De Baetselier I, Manoharan-Basil SS, Van den Bossche D, Kenyon C. WGS of Commensal Neisseria Reveals Acquisition of a New Ribosomal Protection Protein (MsrD) as a Possible Explanation for High Level Azithromycin Resistance in Belgium. Pathogens 2021;10:384. [PMID: 33806962 DOI: 10.3390/pathogens10030384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
34 Van Dijck C, Tsoumanis A, Rotsaert A, Vuylsteke B, Van den Bossche D, Paeleman E, De Baetselier I, Brosius I, Laumen J, Buyze J, Wouters K, Lynen L, Van Esbroeck M, Herssens N, Abdellati S, Declercq S, Reyniers T, Van Herrewege Y, Florence E, Kenyon C. Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial. Lancet Infect Dis 2021;21:657-67. [PMID: 33676596 DOI: 10.1016/S1473-3099(20)30778-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
35 Zimmermann HML, Postma LR, Achterbergh RCA, Reyniers T, Schim van der Loeff MF, Prins M, de Vries HJC, Hoornenborg E, Davidovich U; Amsterdam PrEP Project Team in the HIV Transmission Elimination Amsterdam Initiative (H-TEAM). The Impact of Pre-exposure Prophylaxis on Sexual Well-Being Among Men Who Have Sex with Men. Arch Sex Behav 2021;50:1829-41. [PMID: 33619674 DOI: 10.1007/s10508-020-01833-5] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
36 Zhang J, Xu JJ, Wang HY, Huang XJ, Chen YK, Wang H, Chu ZX, Hu QH, He XQ, Li Y, Zhang LK, Hu ZL, Bao RT, Li SC, Li H, Ding HB, Jiang YJ, Geng WQ, Sylvia S, Shang H; CROPrEP Group. Preference for daily versus on-demand pre-exposure prophylaxis for HIV and correlates among men who have sex with men: the China Real-world Oral PrEP Demonstration study. J Int AIDS Soc 2021;24:e25667. [PMID: 33586841 DOI: 10.1002/jia2.25667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
37 Iniesta C, Coll P, Barberá MJ, García Deltoro M, Camino X, Fagúndez G, Díaz A, Polo R; Spanish Working Group for PrEP. Implementation of pre-exposure prophylaxis programme in Spain. Feasibility of four different delivery models. PLoS One 2021;16:e0246129. [PMID: 33556085 DOI: 10.1371/journal.pone.0246129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Reyniers T, Nöstlinger C, Vuylsteke B, De Baetselier I, Wouters K, Laga M. The Impact of PrEP on the Sex Lives of MSM at High Risk for HIV Infection: Results of a Belgian Cohort. AIDS Behav 2021;25:532-41. [PMID: 32857317 DOI: 10.1007/s10461-020-03010-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Koppe U, Marcus U, Albrecht S, Jansen K, Jessen H, Gunsenheimer-Bartmeyer B, Bremer V. Barriers to using HIV pre-exposure prophylaxis (PrEP) and sexual behaviour after stopping PrEP: a cross-sectional study in Germany. BMC Public Health 2021;21:159. [PMID: 33468089 DOI: 10.1186/s12889-021-10174-4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
40 Zimmermann HML, Jongen VW, Boyd A, Hoornenborg E, Prins M, de Vries HJC, Schim van der Loeff MF, Davidovich U; Amsterdam PrEP Project Team in the HIV Transmission Elimination Amsterdam Initiative (H-TEAM). Decision-making regarding condom use among daily and event-driven users of preexposure prophylaxis in the Netherlands. AIDS 2020;34:2295-304. [PMID: 33196494 DOI: 10.1097/QAD.0000000000002714] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
41 Coyer L, van den Elshout MAM, Achterbergh RCA, Matser A, Schim van der Loeff MF, Davidovich U, de Vries HJC, Prins M, Hoornenborg E, Boyd A; Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative. Understanding pre-exposure prophylaxis (PrEP) regimen use: Switching and discontinuing daily and event-driven PrEP among men who have sex with men. EClinicalMedicine 2020;29-30:100650. [PMID: 33305198 DOI: 10.1016/j.eclinm.2020.100650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
42 Jin F, Dore GJ, Matthews G, Luhmann N, Macdonald V, Bajis S, Baggaley R, Mathers B, Verster A, Grulich AE. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:39-56. [PMID: 33217341 DOI: 10.1016/S2468-1253(20)30303-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
43 Reyniers T, Rotsaert A, Thunissen E, Buffel V, Masquillier C, Van Landeghem E, Vanhamel J, Nöstlinger C, Wouters E, Laga M, Vuylsteke B. Reduced sexual contacts with non-steady partners and less PrEP use among MSM in Belgium during the first weeks of the COVID-19 lockdown: results of an online survey. Sex Transm Infect 2021;97:414-9. [PMID: 33172917 DOI: 10.1136/sextrans-2020-054756] [Cited by in Crossref: 8] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
44 Bauer R, Netzer E, Pintado C, Capitant C, Cua E, Etien N, Fonsart J, Pialoux G, Chidiac C, Etienne C, Doré V, Meyer L, Molina JM; ANRS IPERGAY Study Group. Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial. AIDS Behav 2020;24:3244-51. [PMID: 32350771 DOI: 10.1007/s10461-020-02890-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
45 Kenyon C, Baetselier I, Wouters K. Screening for STIs in PrEP cohorts results in high levels of antimicrobial consumption. Int J STD AIDS 2020;31:1215-8. [PMID: 32903136 DOI: 10.1177/0956462420957519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
46 De Baetselier I, Kenyon C, Vanden Berghe W, Smet H, Wouters K, Van den Bossche D, Vuylsteke B, Crucitti T. An alarming high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium in Belgium: results from samples collected between 2015 and 2018. Sex Transm Infect 2021;97:297-303. [PMID: 32769204 DOI: 10.1136/sextrans-2020-054511] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
47 Mayer KH, Molina J, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, Dejesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, Mccallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. The Lancet 2020;396:239-54. [DOI: 10.1016/s0140-6736(20)31065-5] [Cited by in Crossref: 53] [Cited by in F6Publishing: 100] [Article Influence: 26.5] [Reference Citation Analysis]